BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 19151562)

  • 21. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia.
    Al-Mawali A; Gillis D; Lewis I
    Am J Clin Pathol; 2009 Jan; 131(1):16-26. PubMed ID: 19095561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Present status and perspectives regarding the therapeutic strategy for acute myeloid leukemia, non-Hodgkin's lymphoma and multiple myeloma in the elderly.
    Ohta M
    Geriatr Gerontol Int; 2009 Jun; 9(2):115-23. PubMed ID: 19740353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Correlation of quantification of major bcr-abl mRNA between TMA (transcription mediated amplification) method and real-time quantitative PCR].
    Yagasaki F; Niwa T; Abe A; Ishikawa M; Kato C; Ogura K; Sasaki H; Kyo T; Jinnai I; Bessyo M; Miyamura K
    Rinsho Ketsueki; 2009 Jun; 50(6):481-7. PubMed ID: 19571508
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.
    Sutton R; Venn NC; Tolisano J; Bahar AY; Giles JE; Ashton LJ; Teague L; Rigutto G; Waters K; Marshall GM; Haber M; Norris MD;
    Br J Haematol; 2009 Aug; 146(3):292-9. PubMed ID: 19500099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Marker chromosomes are a significant mechanism of high-level RUNX1 gene amplification in hematologic malignancies.
    Moosavi SA; Sanchez J; Adeyinka A
    Cancer Genet Cytogenet; 2009 Feb; 189(1):24-8. PubMed ID: 19167608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.
    Cilloni D; Renneville A; Hermitte F; Hills RK; Daly S; Jovanovic JV; Gottardi E; Fava M; Schnittger S; Weiss T; Izzo B; Nomdedeu J; van der Heijden A; van der Reijden BA; Jansen JH; van der Velden VH; Ommen H; Preudhomme C; Saglio G; Grimwade D
    J Clin Oncol; 2009 Nov; 27(31):5195-201. PubMed ID: 19752335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantification of free total plasma DNA and minimal residual disease detection in the plasma of children with acute lymphoblastic leukemia.
    Schwarz AK; Stanulla M; Cario G; Flohr T; Sutton R; Möricke A; Anker P; Stroun M; Welte K; Bartram CR; Schrappe M; Schrauder A
    Ann Hematol; 2009 Sep; 88(9):897-905. PubMed ID: 19165483
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Optimising therapy in patients with haematological malignancies].
    Dumontet C
    Bull Cancer; 2008 Oct; 95(10):959-62. PubMed ID: 19004726
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum IL-10 and IL-13 concentrations in patients with haematological malignancies.
    Denizot Y; Turlure P; Bordessoule D; Trimoreau F; Praloran V
    Cytokine; 1999 Aug; 11(8):634-5. PubMed ID: 10433812
    [No Abstract]   [Full Text] [Related]  

  • 30. [Clinical application of metabolic bone markers in hematologic malignancies].
    Hashimoto T; Abe M; Inoue D
    Clin Calcium; 2001 Jul; 11(7):873-8. PubMed ID: 15775592
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibodies and immunohistochemical evaluation for the diagnosis of hematological malignancies: an overview.
    O'Malley DP; Orazi A
    Methods Mol Biol; 2007; 378():91-123. PubMed ID: 18605081
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical studies of histone deacetylase inhibitors.
    Prince HM; Bishton MJ; Harrison SJ
    Clin Cancer Res; 2009 Jun; 15(12):3958-69. PubMed ID: 19509172
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Donor KIR3DL1/3DS1 gene and recipient Bw4 KIR ligand as prognostic markers for outcome in unrelated hematopoietic stem cell transplantation.
    Gagne K; Busson M; Bignon JD; Balère-Appert ML; Loiseau P; Dormoy A; Dubois V; Perrier P; Jollet I; Bois M; Masson D; Moine A; Absi L; Blaise D; Charron D; Raffoux C;
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1366-75. PubMed ID: 19822295
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical significance of serum hepcidin levels on early infectious complications in allogeneic hematopoietic stem cell transplantation.
    Kanda J; Mizumoto C; Kawabata H; Ichinohe T; Tsuchida H; Tomosugi N; Matsuo K; Yamashita K; Kondo T; Ishikawa T; Uchiyama T
    Biol Blood Marrow Transplant; 2009 Aug; 15(8):956-62. PubMed ID: 19589485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Venous thromboembolism in the hematologic malignancies.
    Falanga A; Marchetti M
    J Clin Oncol; 2009 Oct; 27(29):4848-57. PubMed ID: 19752334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
    Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Minimal residual disease in malignant diseases of the blood II. Translation and therapeutic consequences].
    Hokland P; Ommen HB; Nyvold CG; Stentoft J; Braendstrup K; Andersen BL; Mikkelsen LS; Ostergaard M
    Ugeskr Laeger; 2009 Jan; 171(4):232-5. PubMed ID: 19174038
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group.
    Burkhardt B; Reiter A; Landmann E; Lang P; Lassay L; Dickerhoff R; Lakomek M; Henze G; von Stackelberg A
    J Clin Oncol; 2009 Jul; 27(20):3363-9. PubMed ID: 19433688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mesenchymal stem cells remain host-derived independent of the source of the stem-cell graft and conditioning regimen used.
    Bartsch K; Al-Ali H; Reinhardt A; Franke C; Hudecek M; Kamprad M; Tschiedel S; Cross M; Niederwieser D; Gentilini C
    Transplantation; 2009 Jan; 87(2):217-21. PubMed ID: 19155975
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interleukin-17-producing T-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation.
    Dander E; Balduzzi A; Zappa G; Lucchini G; Perseghin P; Andrè V; Todisco E; Rahal D; Migliavacca M; Longoni D; Solinas G; Villa A; Berti E; Mina PD; Parma M; Allavena P; Biagi E; Rovelli A; Biondi A; D'Amico G
    Transplantation; 2009 Dec; 88(11):1261-72. PubMed ID: 19996925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.